Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

By N. Desai, V. Trieu, Z. Yao, Leslie Louie, S. Ci, Andrew Yang, C. Tao, T. De, Bridget Beals, D. Dykes and 5 more. Clinical Cancer Research, 2006

1,109 citations recorded by the source corpus.

Subfields: Cancer Research, Materials Chemistry, Oncology

View Paper: https://www.semanticscholar.org/paper/93e31f26ed7ee967a8fdeba9bf88cdc870e18cd8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. N. Desai
2. O. Farokhzad
3. N. Bertrand
4. Xiaoyang Xu
5. D. Tuveson
6. M. Socinski

In Materials Chemistry

1. O. Farokhzad
2. N. Desai

In Oncology

1. N. Desai
2. O. Farokhzad
3. D. Tuveson

Citations in the corpus

• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “However, these doses were ascertained based on the tolerability of the compound in mice [64].”
• Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, background): “These agents circulate in the body with a half-life about 100 times longer than that of free anticancer drugs while simultaneously reducing systemic toxicity [17-21].”
• The Pancreas Cancer Microenvironment (2012, background): “TME in Pancreatic Ductal Cancer www.aacrjournals.org Clin Cancer Res; 18(16) August 15, 2012 4267 xenograft/allograft models have a fundamentally different composition and functionality of the microenvironment including dramatic differences in the ECM components, immune cells, and tumor vasculature.”
• Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. (2011, result): “In particular, theantitumoractivityofgemcitabineplusnab-paclitaxelcombination therapy may, in part, be explained by the use of the albumin receptor(gp60)–caveolin-1–caveolae–SPARC pathway to increase intratumoral drug concentrations.(33) Although the results of this clinical phase I/II study are pro”
• Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012, background): “In clinical studies, nab-paclitaxel was safe and increased ORR and time to progression in metastatic breast cancer compared with sb-paclitaxel, and it has shown activity in various other advanced solid tumors, including melanoma, pancreatic cancer, and NSCLC.(13-15) In particular, in a dose-finding ”